Risk Factor: C
Class: Autonomics/ Sympathomimetics (adrenergics)
Fetal Risk Summary
Mephentermine is a sympathomimetic used in emergency situations to treat hypotension. Because of the nature of its indication, experience in pregnancy with mephentermine is limited. Mephentermine’s primary action is to increase cardiac output as a result of enhanced cardiac contraction and, to a lesser extent, from peripheral vasoconstriction (1). Its effect on uterine blood flow should be minimal (1).
A newborn infant with complete exstrophy of the bladder, epispadias, widely separated pubic rami, and bilateral inguinal hernias was described in a 1970 publication (2). The infant’s mother, a 19-year-old woman, had used lysergic acid diethylamide (LSD) on at least 1215 occasions during the 2 months before conception and during the first 2.5 months of pregnancy. In addition, she had smoked marijuana twice and had ingested mephentermine sulfate once during the above interval. The cause of the defects observed in the infant is unknown.
Breast Feeding Summary
No data are available.
- Smith NT, Corbascio AN. The use and misuse of pressor agents. Anesthesiology 1970;33:58101.
- Gelehrter TD. Lysergic acid diethylamide (LSD) and exstrophy of the bladder. J Pediatr 1970;77:10656.